La cadena de opciones muestra datos clave de las opciones de acciones de B. Riley Financial a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para B. Riley Financial..

B. Riley Financial (NASDAQ:RILY) Bolsa, Cadena de Opciones

B. Riley Financial

B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.

B. Riley Financial Inc

B. Riley Financial, Inc. - 5.00% Senior Notes due 2026

B. Riley Financial, Inc. - 5.50% Senior Notes Due 2026

B. Riley Financial, Inc. - Depositary Shares, each representing a 1/1000th fractional interest in a share of Series B Cumulative Perpetual Preferred Stock

B Riley Financial Inc 6.375% Sr Nt 02/28/2025

B. Riley Financial, Inc. - 6.50% Senior Notes Due 2026

B Riley Financial Inc 6.750% Sr Nt 05/31/2024

B. Riley Financial, Inc. - Depositary Shares, each representing a 1/1000th fractional interest in a share of Series A Cumulative Perpetual Preferred Stock

B. Riley Financial, Inc. - 6.00% Senior Notes Due 2028

B. Riley Financial, Inc. - 5.25% Senior Notes due 2028

WIIM

BRCC

BRC Announces Proposed Public Offering Of Class A Common Stock; Size Not Disclosed

<p>Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) affirms FY2025 FFO guidance from $2.37-$2.41 to $2.37-$2.41 vs $2.40 analyst estimate..</p>


News

Guidance

REXR

Rexford Industrial Realty Affirms FY2025 FFO Guidance of $2.37-$2.41 vs $2.40 Est

Kinder Morgan Affirms FY2025 Adj EPS Guidance of $1.27 vs $1.27 Est

CREV

Carbon Revolution Announces Nasdaq Non-Compliance Letter

<p>Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) reported quarterly earnings of $0.59 per share which met the analyst consensus estimate. This is a 1.67 percent decrease over earnings of $0.60 per share from the same period last year.  The company reported quarterly sales of $241.568 million which missed the analyst consensus estimate of $248.801 million by 2.91 percent.  This is a 3.69 percent increase over sales of $232.973 million the same period last year.</p>


Earnings

Earnings Misses

Rexford Industrial Realty Q2 FFO $0.59, Inline, Sales $241.568M Miss $248.801M Estimate

<p>AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.01 by 14.85 percent. This is a 31.82 percent increase over earnings of $0.88 per share from the same period last year.  The company reported quarterly sales of $754.500 million which beat the analyst consensus estimate of $695.714 million by 8.45 percent.  This is a 14.93 percent increase over sales of $656.500 million the same period last year.</p>


Earnings Beats

AAR Q4 Adj. EPS $1.16 Beats $1.01 Estimate, Sales $754.500M Beat $695.714M Estimate

<p>Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.27 by 2.56 percent. This is a 12 percent increase over earnings of $0.25 per share from the same period last year.  The company reported quarterly sales of $4.042 billion which beat the analyst consensus estimate of $3.748 billion by 7.86 percent.  This is a 13.16 percent increase over sales of $3.572 billion the same period last year.</p>


Kinder Morgan Q2 Adj. EPS $0.28 Beats $0.27 Estimate, Sales $4.042B Beat $3.748B Estimate

SRPT

Sarepta Therapeutics shares are trading higher after the company announced it will engage in strategic restructuring and cost savings.

<p>This morning, I woke up to the sound of pounding rain on the roof of my bus and a generator that made me decide to take the day off. Add in some flash flooding, a Wi-Fi signal riding on Starlink, and it's already been a day to remember.</p>
<p>But even with all that going on, I had to get a story out to you because we've officially entered one of my favorite times of the year: earnings season.</p>
<p>This isn't just <em>any</em> earnings season, either. It's the second quarter (Q2) earnings, when the biggest batch of reports hits. But while most traders are busy guessing whether a stock will beat or miss expectations, we're going to take a different approach.</p>
<p>So today, I want to walk you through how I'm trading earnings this quarter, the patterns I'm spotting, and the stocks I've got on my radar right now.</p>
<h2 class="wp-block-heading"><em>FREE LIVE EVENT: "It's Like NVIDIA at $10 All Over Again"</em></h2>
<p><em>Tim Melvin is seeing the same setup that preceded NVIDIA's historic run. For the first time ever, he's partnering with trader Anne-Marie Baiynd to reveal where the next explosive opportunities are hiding. [Get Free Access <a href="https://events2.benzinga.com/next-10x-winner/?utm_campaign=072325-webinar&amp;el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD071725">HERE</a>]</em></p>
<h2 class="wp-block-heading">Why Most Traders Blow It on Earnings</h2>
<p>Let's get something out of the way: trading earnings <em>the day before</em> the announcement is a bad idea.</p>
<p>That's what I call "meme trading" or the "Robinhood crowd" mentality. You buy a call because you <em>hope</em> the stock will go up—or a put if you <em>think</em> it'll tank—and hold through earnings. That's a quick way to lose money, even if you're right on direction.</p>
<p>Why? Because of the volatility crush.</p>
<p>Implied volatility usually surges leading into earnings. But once the report drops? Volatility falls off a cliff—often faster than the stock price can move in your favor. That means even if you're "right," you can still lose money because the time premium gets obliterated.</p>
<p>So, what's the better play?  Trade the setup, <em>not</em> the outcome.</p>
<p>That means you want to <strong>get in one to two weeks before earnings</strong>, not the day before. And you want to <strong>get out before the report hits</strong>, selling to someone else who's willing to pay top dollar for all that pumped-up volatility.</p>
<p>I call it <em>"</em>scalping the implied volatility wave."</p>
<p>Now, if I can pair that volatility ramp with a strong directional pattern, that's where the real edge comes in. Some stocks tend to drift higher (or lower) into earnings like clockwork. And when price and volatility rise together, that's our signal to strike, which brings me to a few setups I've got my eye on.</p>
<h2 class="wp-block-heading">Pan American Silver</h2>
<p>I've been watching <strong>Pan American Silver </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) for a while. Over the last four quarters, PAAS has sold off in the week leading up to earnings, and each time, implied volatility has spiked. That's a textbook setup for put buyers.</p>
<p>Now, earnings aren't coming until August 6, but that gives us time to prepare. I'll be watching closely for the next dip and any IV surge. If we see both, I'll be looking to grab short-term options and ride them for a few days before the announcement.</p>
<h2 class="wp-block-heading">AbbVie</h2>
<p><strong>AbbVie </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is the opposite of PAAS. This one has a bullish pattern leading up to earnings, with the stock moving higher ahead of the last few reports. Same deal—volatility ramps, price climbs, and that creates a sweet spot for call options.</p>
<p>Earnings drop on July 30, so again, we've got time. I'll be eyeing this one about 10 days out, especially if we see any early pullbacks that offer a cheaper entry.</p>
<h2 class="wp-block-heading">Why This Matters And What To Do Next</h2>
<p>A lot of traders think earnings are binary: either the stock beats expectations and pops, or it misses and crashes. But that's not how the smart money trades.</p>
<p>We're not gambling on outcomes, we're stacking probabilities.</p>
<p>We're looking for patterns that have played out multiple times, we're aligning with the natural volatility cycle, and we're getting out before the crowd even shows up.</p>
<p>Remember, I track the top 325 stocks every quarter to find these patterns. PAAS and ABBV are just two names with strong historical setups—but they're not the only ones. The more you study these moves, the easier it gets to spot consistent winners.</p>
<p>This week, I'll be running more scans and breaking down a few ETF setups as well (seasonality is back in play). And of course, I'll be keeping one eye on the headlines. After all, even a strong earnings setup can get shaken up by the 24/7 news cycle.</p>
<p>Until then, keep your watchlists tight, your entries clean, and your exits earlier than everyone else.</p>
<p><em>Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.</em></p>
<p><em>Photo: Shutterstock</em></p>


Opinion

Trading Ideas

ABBV

PAAS

My Top 2 Earnings Picks For This Earnings Season

<p><i><strong>Executive Leadership Appointments</strong></i><br /><br />In conjunction with the restructuring, Sarepta announced key executive appointments:</p>
<ul>
<li>Ian Estepan named President and Chief Operating Officer</li>
<li>Louise Rodino-Klapac, Ph.D., named President of Research &amp; Development and Technical Operations</li>
<li>Ryan Wong, named Chief Financial Officer, previously Senior Vice President of Strategic Finance, Treasury, and Investor Relations</li>
<li>Rachael Potter, Ph.D., named Chief Scientific Officer, previously Senior Vice President, Head of Research Sciences</li>
<li>Patrick Moss, Pharm.D., named Chief Commercial Officer, previously Senior Vice President of U.S. Market Access and Sales, succeeding Dallan Murray, Chief Customer Officer, who is leaving Sarepta. The Company thanks Mr. Murray for his long-time service and wishes him well.</li>
</ul>


Management

Sarepta Therapeutics Announces Ian Estepan Named President And Chief Operating Officer; Ryan Wong, Named Chief Financial Officer

United Airlines Sees 6-Point Acceleration In Booking Demand In July; Expects Less Geopolitical, Macroeconomic Uncertainty In H2 2025

MMLP

Martin Midstream Partners Reaffirms FY Adj. EBITDA Guidance Of $109.1M

<p>– <i><strong>After strategic review, Sarepta focuses pipeline on high-impact programs, prioritizing potentially best-in-class siRNA platform assets</strong></i></p>
<p>– <i><strong>Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36% workforce reduction of approximately 500 employees</strong></i></p>
<p>– <i><strong>Duchenne portfolio continues to deliver stable and robust revenues, with preliminary quarterly results showing total net product revenue of $513 million for the second quarter 2025</strong></i></p>
<p>– <i><strong>U.S. FDA has requested and Sarepta has agreed to include a black box warning in the ELEVIDYS label, resolving any material issues with the ambulant population indication</strong></i></p>
<p>– <i><strong>Sarepta has completed an Expert Committee on a protocol for the use of additional prophylactic immunosuppression for non-ambulant patients, and will submit the protocol to FDA imminently and discuss the pathway to resume shipment of ELEVIDYS for non-ambulant patients</strong></i></p>
<p>– <i><strong>Company to host investor call on July 16, 2025, at 4:30 p.m. Eastern time</strong></i></p>
<p>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan designed to prioritize high-value, high impact programs, meet its 2027 financial obligations, and support its long-term financial viability. This plan is expected to position the Company for long-term sustainable growth, with an emphasis on near- and mid-term opportunities from the siRNA platform. These decisive changes aim to ensure sustained profitability and preserve the Company's ability to deliver on its mission of advancing innovative medicines for those with rare genetic diseases.</p>


Biotech

General

Sarepta Announces Strategic Restructuring With 36% Workforce Reduction And $400M In Annual Cost Savings, Refocuses Pipeline On siRNA Assets; Reports $513M In Q2 Revenue And Resolving FDA Issues For ELEVIDYS

<p>Martin Midstream Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMLP#NASDAQ">MMLP</a>) reported quarterly losses of $(0.06) per share. This is a 166.67 percent decrease over earnings of $0.09 per share from the same period last year.  The company reported $180.676 million in sales this quarter. This is a 2.09 percent decrease over sales of $184.531 million the same period last year.</p>


Martin Midstream Partners Q2 EPS $(0.06) Down From $0.09 YoY, Sales $180.676M Down From $184.531M YoY

MCRI

Monarch Casino & Resort Q2 EPS $1.44 Beats $1.22 Estimate, Sales $136.914M Beat $129.834M Estimate

<p>United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) lowers FY2025 Adj EPS guidance from $11.50-$13.50 to $9.00-$11.00 vs $10.05 analyst estimate..</p>


United Airlines Holdings Lowers FY2025 Adj EPS Guidance from $11.50-$13.50 to $9.00-$11.00 vs $10.05 Est

<p>Across the recent three months, 4 analysts have shared their insights on Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.5, a high estimate of $105.00, and a low estimate of $81.00. Observing a downward trend, the current average is 2.33% lower than the prior average price target of $96.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752696064_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Monarch Casino &amp; Resort. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Jeffrey Stantial</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$81.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Monarch Casino &amp; Resort. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Monarch Casino &amp; Resort compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Monarch Casino &amp; Resort's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Monarch Casino &amp; Resort's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MCRI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Monarch Casino &amp; Resort analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Delving into Monarch Casino &amp; Resort's Background</h2>
<p>Monarch Casino &amp; Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food &amp; Beverage and Hotel Operations.</p>
<h3>Financial Insights: Monarch Casino &amp; Resort</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Monarch Casino &amp; Resort displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>3.07%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Monarch Casino &amp; Resort's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>15.84%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Monarch Casino &amp; Resort's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.77%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.83%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Monarch Casino &amp; Resort's debt-to-equity ratio is below the industry average at <strong>0.03</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

A Glimpse Into The Expert Outlook On Monarch Casino & Resort Through 4 Analysts

<p>Financial giants have made a conspicuous bearish move on Cigna Group. Our analysis of options history for Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) revealed 17 unusual trades.</p>
<p>Delving into the details, we found 23% of traders were bullish, while 64% showed bearish tendencies. Out of all the trades we spotted, 13 were puts, with a value of $765,142, and 4 were calls, valued at $432,675.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $300.0 and $340.0 for Cigna Group, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Cigna Group's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Cigna Group's substantial trades, within a strike price spectrum from $300.0 to $340.0 over the preceding 30 days.</p>
<h3>Cigna Group Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752696057_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$51.8</td>
<td>$50.2</td>
<td>$50.2</td>
<td>$300.00</td>
<td>$336.3K</td>
<td>309</td>
<td align="right">70</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$13.9</td>
<td>$12.5</td>
<td>$12.5</td>
<td>$315.00</td>
<td>$108.7K</td>
<td>1.2K</td>
<td align="right">500</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$14.0</td>
<td>$12.9</td>
<td>$12.9</td>
<td>$315.00</td>
<td>$96.7K</td>
<td>1.2K</td>
<td align="right">581</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$12.8</td>
<td>$12.4</td>
<td>$12.8</td>
<td>$315.00</td>
<td>$64.4K</td>
<td>1.2K</td>
<td align="right">631</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$12.7</td>
<td>$12.3</td>
<td>$12.7</td>
<td>$315.00</td>
<td>$54.6K</td>
<td>1.2K</td>
<td align="right">337</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cigna Group</h3>
<p>Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.</p>
<p>After a thorough review of the options trading surrounding Cigna Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Cigna Group's Current Market Status</h3>
<ul>
<li>With a trading volume of 894,988, the price of CI is up by 1.04%, reaching $305.6.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 15 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Cigna Group</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $371.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $371.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cigna Group options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

Cigna Group Options Trading: A Deep Dive into Market Sentiment

<p>4 analysts have expressed a variety of opinions on PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $11.06, with a high estimate of $11.50 and a low estimate of $10.75. This current average has decreased by 5.87% from the previous average price target of $11.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752696055_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive PennantPark Floating Rate. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vilas Abraham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.75</td>
<td>$10.50</td>
</tr>
<tr>
<td>Matthew Condon</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Michael Diana</td>
<td>Maxim Group</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.50</td>
<td>$12.50</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PennantPark Floating Rate. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of PennantPark Floating Rate compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of PennantPark Floating Rate's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of PennantPark Floating Rate's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PFLT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on PennantPark Floating Rate analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About PennantPark Floating Rate</h2>
<p>PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.</p>
<h3>Breaking Down PennantPark Floating Rate's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, PennantPark Floating Rate faced challenges, resulting in a decline of approximately <strong>-90.1%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> PennantPark Floating Rate's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>37.18%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> PennantPark Floating Rate's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.12%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> PennantPark Floating Rate's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.05%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.28</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PFLT

Analyst Expectations For PennantPark Floating Rate's Future

<p>Deep-pocketed investors have adopted a bearish approach towards Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NKE usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 28 extraordinary options activities for Nike. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 35% leaning bullish and 46% bearish. Among these notable options, 8 are puts, totaling $1,070,292, and 20 are calls, amounting to $1,667,454.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $95.0 for Nike over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Nike's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Nike's whale trades within a strike price range from $50.0 to $95.0 in the last 30 days. </p>
<h3>Nike Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752696052_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$10.2</td>
<td>$10.05</td>
<td>$10.1</td>
<td>$75.00</td>
<td>$505.0K</td>
<td>606</td>
<td align="right">502</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.05</td>
<td>$7.9</td>
<td>$8.05</td>
<td>$75.00</td>
<td>$362.2K</td>
<td>13.6K</td>
<td align="right">450</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/17/27</td>
<td>$28.8</td>
<td>$27.9</td>
<td>$28.8</td>
<td>$50.00</td>
<td>$288.0K</td>
<td>775</td>
<td align="right">302</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/17/27</td>
<td>$28.75</td>
<td>$28.7</td>
<td>$28.7</td>
<td>$50.00</td>
<td>$284.1K</td>
<td>775</td>
<td align="right">202</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/17/27</td>
<td>$29.05</td>
<td>$28.75</td>
<td>$28.8</td>
<td>$50.00</td>
<td>$146.7K</td>
<td>775</td>
<td align="right">52</td>
</tr>
</tbody>
</table>
</p>
<h3>About Nike</h3>
<p>Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.</p>
<h3>Nike's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 6,679,254, the NKE's price is up by 0.01%, now at $72.0. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 76 days.</li>
</ul>
<h3>Expert Opinions on Nike</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $80.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; In a positive move, an analyst from Argus Research has upgraded their rating to Buy and adjusted the price target to $85.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on Nike, maintaining a target price of $73.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Nike with a target price of $85.<br />
&#x2A; An analyst from Deutsche Bank persists with their Buy rating on Nike, maintaining a target price of $71.<br />
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Nike, targeting a price of $90. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Nike options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Unpacking the Latest Options Trading Trends in Nike

Press Releases

B. Riley Financial Announces Private Bond Exchange to Reduce Debt by Approximately $12 Million

B. Riley Financial Announces CFO Transition

B. Riley Financial Announces Private Bond Exchange to Reduce Debt by Approximately $46 Million

Peraso Inc.'s (NASDAQ: PRSO) Beamforming Technology Gains Military Traction – See More Stocks Inside

B. Riley Financial Announces Notification of Delinquency with Nasdaq

B. Riley Financial Granted Extension From Nasdaq Regarding Listing Rules

B. Riley Financial Announces the $117.8 Million Sale of GlassRatner to TorQuest Partners

B. Riley Financial Reduces Debt by Approximately $15 Million via Private Bond Exchange

B. Riley Financial Amends Senior Credit Facility with Oaktree

B. Riley Financial Reduces Debt by Approximately $18 Million via Private Bond Exchange

AKYA

ASST

EDBL

PRSO

RILY

SGMA

SNYR

AMTD IDEA Group American Depositary Shares, each representing six (6) Class A Ordinary Shares

AMTD IDEA

AtlasClear Holdings

Dominari Holdings

Etoro Group

Grande Group Limited - Class A Ordinary Shares

Grande Group

Garden Stage

Lion Group Holding Ltd. - American Depositary Share

Lion Group Holding

MDB Capital Holdings, LLC - Class A common

MDB Capital Holdings

Magic Empire Global Limited - Class A Ordinary Shares

Magic Empire Glb

mF International Limited - Class A Ordinary Shares

mF International

Marex Group

Oppenheimer Holdings, Inc. Class A Common Stock (DE)

Oppenheimer Hldgs

PJT Partners

Plutus Financial Group Limited - Ordinary Shares

Plutus Financial Group

Perella Weinberg Partners - Class A Common Stock

Perella Weinberg

Siebert Finl

StoneX Group

Solowin Holdings - Class A Ordinary Share

Solowin Holdings

UP Fintech Holding Limited - American Depositary Shares representing fifteen Class A Ordinary Shares

UP Fintech Holding

TOP Financial Group Limited - Class A Ordinary Shares

TOP Finl Gr

Virtu Financial, Inc. Class A Common Stock

Virtu Finl

Top KingWin Ltd - Class A Ordinary Shares

Top KingWin

Waton Financial Limited - Ordinary Shares

Comments

B. Riley Financial

B. Riley Financial (RILY) Opciones

B. Riley Financial (NASDAQ:RILY) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL